Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Journal article published in 2019 by
Laura Rosiñol 
,
Albert Oriol ,
Rafael Rios ,
Anna Sureda,
María Jesús Blanchard,
Miguel Teodoro Hernández,
Rafael Martínez-Martínez,
Jose M. Moraleda,
Isidro Jarque ,
Juan Bargay,
Mercedes Gironella,
Felipe de Arriba,
Luis Palomera,
Yolanda González-Montes,
Josep M. Martí
and other authors.
,
Albert Oriol ,
Rafael Rios ,
Anna Sureda,
María Jesús Blanchard,
Miguel Teodoro Hernández,
Rafael Martínez-Martínez,
Jose M. Moraleda,
Isidro Jarque ,
Juan Bargay,
Mercedes Gironella,
Felipe de Arriba,
Luis Palomera,
Yolanda González-Montes,
Josep M. Martí
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key PointsVRD was effective and well tolerated before ASCT; 33.4% complete response/28.8% minimal residual disease–negative after 6 induction cycles. Responses deepened with VRD throughout induction and over the course of treatment with few discontinuations due to toxicity.